Mingxi Yu
Advanced Heart Failure and Transplant Cardiology · Maywood, ILNPI 1629497557
Payments from drug & device makers
What this record shows
This record is dominated by grants: $35,000 of the $37,800 with a category attached, or 92.6%. 16 manufacturers reported payments, led by Abbott at 55.4% of the total. Reporting peaked in 2020 at $35,142 and has fallen 99.3% since, to $257 in 2025.
Across 59 payments — averaging $640.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$21K
- Medtronic$15K
- Johnson & Johnson$342
- Abiomed$333
- Novartis$329
- Bridgebio Pharma, Inc.$162
- plus $695 from 10 others
What the payments were for
- Grants$35,00093%
- Food & beverage$2,8007%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 19 | $20,939 |
| Medtronic | 1 | $15,000 |
| Johnson & Johnson | 5 | $342 |
| Abiomed | 5 | $333 |
| Novartis | 8 | $329 |
| Bridgebio Pharma, Inc. | 5 | $162 |
| Novo Nordisk | 2 | $150 |
| Cvrx, Inc. | 3 | $149 |
| Amgen | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $88 |
| Pfizer | 2 | $64 |
| Livanova USA, Inc. | 1 | $31 |
| Alnylam Pharmaceuticals Inc. | 1 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $23 |
| Biosense Webster, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Endurant$15,000
- XARELTO$226
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$222
- ENSITE PRECISION$163
- MitraClip$153
- Repatha$125
- Ozempic$125
- ENTRESTO$120
- Attruby$105
How this compares
$37,800 in reported general payments places this provider in the 70th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
See all advanced heart failure and transplant cardiology providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 44 | $1,095,174 |
| EntrestoSacubitril/Valsartan | 94 | $156,732 |
| JardianceEmpagliflozin | 70 | $89,781 |
| EliquisApixaban | 62 | $75,518 |
| FarxigaDapagliflozin Propanediol | 43 | $55,868 |
| OzempicSemaglutide | 20 | $20,706 |
| Bumetanide | 54 | $2,524 |
| Potassium Chloride | 38 | $2,488 |
| Metoprolol Succinate | 145 | $2,317 |
| Hydralazine Hcl | 41 | $1,003 |
| Carvedilol | 75 | $801 |
| Torsemide | 31 | $796 |
| Spironolactone | 89 | $790 |
| Atorvastatin Calcium | 76 | $669 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 27 | $645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $64 | $1,170,692106 claims |
| NovartisEntresto | $329 | $156,73294 claims |
| Novo NordiskOzempic | $150 | $20,70620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.
Other advanced heart failure and transplant cardiology in Maywood
- Naofumi YamamotoMaywood$20K
- Joshua NewmanMaywood$3K
- Maria Rosa CostanzoNaperville$716K
- Jonathan RichChicago$327K
- Esther VorovichChicago$224K
- Jane WilcoxChicago$220K
- Ali ValikaElmhurst$218K
- Manreet KanwarChicago$162K
- Jonathan GrinsteinChicago$128K
- Muhyaldee DiaOak Lawn$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.